Featured Publications
Head-to-head comparison of the dual-MEK inhibitor IMM-1-104 versus binimetinib in NRAS mutant melanoma models
Virtual poster released on Jan 6, 2022
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery
IMM-1-104: a novel, oral, selective dual-MEK inhibitor that displays broad antitumor activity and high tolerability across RAS and RAF mutant tumors in vivo
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P252,
Presenter: Brett Hall, Ph.D., Immuneering Chief Scientific Officer
Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P240
Presenter: Peter King, Ph.D., Immuneering Vice President, Head of Discovery
Transcriptional effects in C26 tumor highlight mechanistic aspects of a novel dual MEK inhibitor, IMM-1-104
Virtual poster presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021
Poster #: P254
Presenter: Sarah Kolitz, Ph.D., Immuneering Vice President, Translational Medicine
Publications
Page 1 of 8
November 10, 2022
Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the Dual MEK inhibitor, IMM-6-415, enhances PD-1 and CTLA-4 checkpoint blockade in RAS mutant tumors
KRAS is the most frequently altered RAS gene (~85%) and is often mutated in pancreatic ductal adenocarcinoma (PDAC; 95%), non-small cell lung cancer (NSCLC; 40%) and colorectal cancer (CRC; 45%)1….
May 26, 2022
Translational Modeling for Patients with RAS Mutant Tumors: Profiling the Dual-MEK Inhibitor IMM-1-104 in a Humanized 3D Assay
Background: Elevated RAS-RAF-MEK-ERK (MAPK pathway) signaling is observed in over half of all solid human tumors, and mutations in RAS or RAF account for a large fraction. Given MEK’s unique…
Head-to-Head Comparison of the Dual-MEK Inhibitor IMM-1-104 versus Sotorasib or Adagrasib in KRAS Mutant Pancreatic Tumors
Background: KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC). While 90% of PDAC tumors display activating mutations in KRAS, only ~2% are G12C, a specific KRAS mutation targeted by…
January 3, 2022
Assessing reproducibility of inherited variants detected with short-read whole genome sequencing
Background Reproducible detection of inherited variants with whole genome sequencing (WGS) is vital for the implementation of precision medicine and is a complicated process in which each step affects variant…
Journal: Genome Biology
December 10, 2021
FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology
Abstract: Cancer is the second leading cause of mortality worldwide despite tremendous advances in treatment. The promise of precision oncology depends on accurate characterization of tumor mutations and subsequent therapy selection….
Journal: Precision Cancer Medicine
November 17, 2021
Reporting guidelines for human microbiome research: the STORMS checklist
The particularly interdisciplinary nature of human microbiome research makes the organization and reporting of results spanning epidemiology, biology, bioinformatics, translational medicine and statistics a challenge. Commonly used reporting guidelines for…
Journal: Nature Medicine
November 3, 2021
Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA
Despite an increasing demand for precision medicine enabled by NGS measurement of actionable mutations in circulating tumor DNA (ctDNA) specimens, the ability to reliably measure and report low-frequency mutations using…
Journal: Cell Reports
October 4, 2021
Orchestrating and sharing large multimodal data for transparent and reproducible research
Reproducibility is essential to open science, as there is limited relevance for findings that can not be reproduced by independent research groups, regardless of its validity. It is therefore crucial…
Journal: Nature Communications
September 9, 2021
Establishing community reference samples, data and call sets for benchmarking cancer mutation detection using whole-genome sequencing
The lack of samples for generating standardized DNA datasets for setting up a sequencing pipeline or benchmarking the performance of different algorithms limits the implementation and uptake of cancer genomics….
Journal: Nature Biotechnology
Toward best practice in cancer mutation detection with whole-genome and whole-exome sequencing
Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study…
Journal: Nature Biotechnology
Page 1 of 8
